Application > World market of anticancer drugs After approval by the FDA in the United States as an anticancer agent against ovarian cancer in 1992, breast cancer in 1994 and Kaposi's sarcoma in 1997, application of paclitaxel was broadened to rheumatoid arthritis. Over 180 clinical trials with other therapies are being tested. It is anticipated that the $1.4 billion world market share of paclitaxel in 1998 will expand up to $2.7 billion in 2002.